Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in AML Induction Chemotherapy
NCT01890746Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of eltrombopag in acute myeloid leukemia (AML), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
eltrombopag
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01890746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01890746.